Advertisement

Importance of 1-Methyltetrahydroisoquinoline (1MeTIQ) in Parkinson’s Disease

  • Shigeru Ohta
  • Yoshikazu Tasaki
  • Yukiko Makino
  • Osamu Tachikawa
  • Masaaki Hirobe
Part of the Advances in Behavioral Biology book series (ABBI, volume 38A)

Abstract

The existence of endogenous 1-methyl-l,2,3,4-tetrahydro-isoquinoline (1MeTIQ) accompanied with 1,2,3,4-tetrahydro-isoquinoline (TIQ) in the rat brain has been confirmed in our previous research.1 The possibility of TIQ and 1MeTIQ intake from some foods was also pointed out.2 Recently, the neurotoxic properties of TIQ have been discussed, especially with regard to Parkinson’s disease.3–7 In spite of structural similarity to TIQ, there has been no study for the role of 1MeTIQ, the structure of which is shown in Fig. 1, in Parkinson’s disease, except for our work that confirmed a decrease in 1MeTIQ content in parkinsonian brain.8

Keywords

Tyrosine Hydroxylase Endogenous Substance Pole Test Normal Human Brain Intracerebral Microdialysis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    M. Kohno, S. Ohta, and M. Hirobe, Tetrahydroisoquinoline and 1-methyl-tetrahydroisoquinoline as novel endogenous amines in rat brain, Biochem. Biophys. Res. Commun. 140: 448 (1986).PubMedCrossRefGoogle Scholar
  2. 2.
    Y. Makino, S. Ohta, O. Tachikawa, and M. Hirobe, Presence of tetrahydroisoquinoline and l-methyltetrahydroisoquinoline in foods: compounds related to Parkinson’s disease, Life Sci. 43: 373 (1988).PubMedCrossRefGoogle Scholar
  3. 3.
    K. Suzuki, Y. Mizuno, and M. Yoshida, Inhibition of mitochondrial NADH-ubiquinone oxidoreductase activity and ATP synthesis by tetrahydroisoquinoline, Neurosci. Lett. 86: 105 (1988).PubMedCrossRefGoogle Scholar
  4. 4.
    K. Koike, I. Takayanagi, S. Wani, T. Yanagita, S. Ohta, and M. Hirobe, Effect of tetrahydroisoquinoline (TIQ), one of endogenous substances inducing parkinsonism, on isolated rat vas deferens, Gen. Pharmacol. 20: 259 (1989).PubMedCrossRefGoogle Scholar
  5. 5.
    T. Nagatsu, and M. Yoshida, An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions, Neurosci. Lett. 87: 178 (1988).PubMedCrossRefGoogle Scholar
  6. 6.
    T.L. Perry, K. Jones, and S. Hansen, Tetrahydroisoquinoline lacks dopamininergic nigrostriatal neurotoxicity in mice, Neurosci. Lett. 85: 101 (1988).PubMedCrossRefGoogle Scholar
  7. 7.
    R. G. Booth, N. Castagnoli Jr, and H. Rollema, Intracerebral microdialysis neurotoxicity studies of quinoline and isoquinoline derivatives related to MPTP/MPP, Neurosci. Lett. 100: 306 (1989).PubMedCrossRefGoogle Scholar
  8. 8.
    S. Ohta, M. Kohno, Y. Makino, O. Tachikawa, and M. Hirobe, Tetrahydroisoquinoline and 1-methyltetrahydroisoquinoline are present in the human brain: relation to Parkinson’s disease, Biomed. Res. 8: 453 (1987).Google Scholar
  9. 9.
    N. Ogawa, Y. Hirose, S. Ohara, T. Ono, and Y. Watanabe, A simple quantitative bradykinesia test in MPTP-treated mice, Res. Commun. Chem. Pathol. Pharmacol. 50: 435 (1985).PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1990

Authors and Affiliations

  • Shigeru Ohta
    • 1
  • Yoshikazu Tasaki
    • 1
  • Yukiko Makino
    • 1
  • Osamu Tachikawa
    • 1
  • Masaaki Hirobe
    • 1
  1. 1.Faculty of Pharmaceutical SciencesUniversity of TokyoBunkyo-ku, TokyoJapan

Personalised recommendations